Overview

The IllumiNeuro Protocol is a structured multimodal approach to cognitive enhancement that integrates photobiomodulation (PBM) therapy with a curated combination of nootropic compounds and neuroprotective agents. Photobiomodulation, which applies near-infrared (NIR) light at wavelengths of 810–1100 nm to the scalp, stimulates cytochrome c oxidase in neuronal mitochondria, enhancing ATP production, reducing oxidative stress, and increasing cerebral blood flow. The protocol pairs this physical modality with synergistic nutritional and peptide-based compounds to amplify neuroplasticity, memory consolidation, and overall cognitive resilience.

The protocol typically incorporates compounds with complementary mechanisms of action across multiple neurological targets. Mitochondrial energy support may include coq10, pqq, and nad-plus to sustain the metabolic enhancements initiated by PBM. Neurotrophic support often features semax or selank for BDNF upregulation, while cholinergic optimization may involve alpha-gpc and huperzine-a. Anti-inflammatory and neuroprotective layers can include lion-s-mane for nerve growth factor stimulation and dihexa for hepatocyte growth factor potentiation. The combination of transcranial PBM with these targeted compounds aims to create a comprehensive neurocognitive environment that exceeds what any single intervention could achieve.

Clinical research on transcranial PBM has shown promise in mild traumatic brain injury, age-related cognitive decline, and depression, with improvements in executive function, attention, and memory. By layering PBM with evidence-based nootropics, the IllumiNeuro Protocol seeks to address cognitive enhancement through multiple convergent pathways — mitochondrial bioenergetics, synaptic plasticity, neuroinflammation, and neurotransmitter balance. Individual compound selection and dosing are typically customized based on cognitive goals, baseline neurotransmitter status, and individual response. The protocol represents a growing trend in integrative neuroscience toward multi-target, personalized cognitive optimization strategies.

Mechanism of Action

The IllumiNeuro Protocol combines four peptides that target complementary neurological pathways. PE-22-28, derived from the carboxyl-terminal fragment of pro-opiomelanocortin (POMC), acts primarily through sphingosine-1-phosphate (S1P) receptor modulation. By engaging S1P receptors on neuronal membranes, PE-22-28 activates downstream Akt/mTOR signaling cascades that promote neurite outgrowth, synaptic plasticity, and neuronal survival. This peptide has demonstrated the ability to enhance neural connectivity and support the formation of new synaptic connections. Pinealon (Glu-Asp-Arg) is a short bioregulatory peptide that targets the pineal gland and central nervous system. It modulates the expression of genes involved in melatonin synthesis and circadian rhythm regulation, primarily through interactions with chromatin remodeling complexes. By supporting healthy pineal function, Pinealon helps normalize sleep-wake cycles and provides neuroprotective effects through enhanced antioxidant defense mechanisms associated with melatonin signaling.

NA-Semax Amidate is a modified version of the ACTH(4-10) fragment with enhanced blood-brain barrier penetration due to its N-acetyl and C-amide modifications. Its primary mechanism involves upregulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB, activating the MAPK/ERK and PI3K/Akt signaling pathways. This leads to enhanced neuronal survival, synaptic plasticity, and long-term potentiation. Additionally, NA-Semax Amidate modulates the expression of neurotrophins NGF and NT-3, and influences immune function through effects on cytokine expression. NA-Selank Amidate, derived from the endogenous tetrapeptide tuftsin with a D-Arg-Pro-Gly-Pro extension, acts primarily through GABAergic modulation, enhancing the stability and binding affinity of GABA at GABA-A receptors. It also influences the enkephalin system and modulates IL-6 and other cytokine levels, providing anxiolytic and immunomodulatory effects. The N-acetyl and amide modifications improve metabolic stability and CNS penetration.

When combined, these four peptides create a synergistic neurological protocol. PE-22-28 drives structural neural connectivity, Pinealon optimizes circadian and neuroendocrine function, NA-Semax Amidate provides neurotrophic support and cognitive enhancement, and NA-Selank Amidate delivers anxiolytic balance and immune-neuroendocrine regulation. The protocol theoretically addresses multiple dimensions of brain health: neuroplasticity, neuroprotection, cognitive performance, mood regulation, and sleep quality through complementary receptor systems and signaling cascades.

Reconstitution Calculator

Safety Profile

Safety Profile: IllumiNeuro Protocol

Common Side Effects

• Component-dependent variability: side effects depend on the specific compounds included in the protocol formulation (typically a multi-ingredient nootropic stack)
• Gastrointestinal discomfort: nausea, bloating, or mild diarrhea from combined supplement burden
• Headache, particularly during initial adaptation period
• Mild insomnia or sleep disturbance if taken too late in the day
• Overstimulation symptoms: jitteriness, restlessness, or difficulty concentrating (paradoxical)

Serious Adverse Effects

• Multi-ingredient interaction risk: proprietary blends combining multiple neuroactive compounds increase the probability of unpredictable pharmacological interactions
• Serotonin syndrome risk: if the protocol includes serotonergic compounds (5-HTP, tryptophan, St. John's wort) combined with prescription antidepressants
• Hepatotoxicity: stacking multiple supplements metabolized by the liver increases cumulative hepatic burden
• Adrenal or HPA axis disruption: protocols including adaptogens, stimulants, or cortisol modulators may dysregulate the stress-response axis with chronic use
• Quality control concerns: multi-ingredient formulations from unregulated sources may have inconsistent dosing or contamination

Contraindications

• Concurrent use of prescription psychiatric medications (SSRIs, SNRIs, MAOIs, benzodiazepines) without physician clearance
• History of seizure disorders (multiple neuroactive compounds may lower seizure threshold)
• Severe hepatic or renal impairment
• Known allergy to any component ingredient
• Pregnancy or breastfeeding

Drug Interactions

• Psychiatric medications: high risk of interactions depending on stack composition; serotonergic, dopaminergic, and GABAergic components may potentiate or antagonize prescription drugs
• Blood thinners: many nootropic ingredients (fish oil, ginkgo, vitamin E) have antiplatelet properties; cumulative bleeding risk
• Thyroid medications: iodine, ashwagandha, or other thyroid-active components may alter levothyroxine requirements
• CYP450 substrates: multiple botanical ingredients may induce or inhibit hepatic enzymes, affecting drug metabolism unpredictably
• Caffeine and stimulants: additive CNS stimulation if the protocol includes stimulatory compounds

Population-Specific Considerations

• Pregnancy / lactation: contraindicated — multi-ingredient stacks lack safety data in pregnancy; individual components may carry teratogenic risk
• Children / adolescents: not recommended; developing brains require caution with neuroactive compound combinations
• Elderly: start with reduced doses of all components; polypharmacy risk is significantly elevated
• Individuals with mental health conditions: consult a psychiatrist before initiating; effects on neurotransmitter balance are complex and unpredictable
• General caution: as a proprietary protocol, independent verification of ingredient identity, purity, and dose is essential; request certificates of analysis

Pharmacokinetic Profile